BVS - Bioventus receives FDA clearance for BoneScalpel Access

Bioventus (NASDAQ:BVS) perks up 3% premarket after announcing that the FDA has granted 510(k) clearance for its neXus BoneScalpel Access handpiece. The neXus system combines all the features of soft and hard (e.g. bone) tissue removal into a single fully integrated offering. “The BoneScalpel Access handpiece provides surgeons with a new option for confined spaces during minimally invasive surgery, enabling safe and powerful bone removal with maximum visualization,” said Sharon Klugewicz, Senior Vice President, Quality and Regulatory Affairs, Bioventus. Bioventus plans to launch BoneScalpel Access in 2022. The neXus Ultrasonic Surgical Aspirator System has been commercialized successfully in the US, Canada, Europe, and Australia.

For further details see:

Bioventus receives FDA clearance for BoneScalpel Access